Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ChemDiv, Lilly Expanded Discovery Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ChemDiv, Lilly Expanded Discovery Pact

ChemDiv, Inc. and Lilly have expanded their drug discovery collaboration through 2010.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ChemDiv, Inc. and Lilly have expanded their drug discovery collaboration through 2010. The two companies will identify and develop leads for an additional therapeutic target using ChemDiv’s small molecule resources and Discovery outSource platforms.

The collaboration began in January 2004 to discover and develop leads and research tools across multiple therapeutic areas. With this agreement, Lilly has continued access to ChemDiv’s Discovery outSource services for preclinical and clinical development, with expertise in CNS, oncology, inflammation and metabolic disorders. The therapeutic target and financial terms were not disclosed.

“We are pleased to extend our successful collaboration with Lilly with a new therapeutic target,” said Ron Demuth, senior vice president of ChemDiv. “We are delighted to have this opportunity to deliver superior value for our partner’s R&D portfolio.”

Read Lilly’s profile in this year’s Top 20 Pharma Report!


Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics